Reductions in neuropsychiatric symptoms after lecanemab treatment and their associations with imaging markers of β-amyloid clearance

Background: Anti–amyloid-β (Aβ) therapies can slow cognitive decline and reduce cerebral amyloid burden in Alzheimer’s disease (AD). Neuropsychiatric symptoms (NPS) are highly prevalent across the disease course and substantially contribute to disability and caregiver burden. However, whether Aβ cle...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yaping Yan, Daoyan Hu, Linlin Kong, Kaicheng Li, Jun Su, Yingzhe Wu, Hongwei Zhan, Hong Zhang, Yidan Sun, Xiaofeng Dou, Peiyu Huang, Jiong Zhou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2026-08-01
Edice:	The Journal of Prevention of Alzheimer's Disease
Témata:	Alzheimer’s disease Lecanemab Neuropsychiatric symptoms Aβ clearance
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2274580726001251
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!